Middle East IVD Market – Opportunity Analysis and Industry Forecast (2024-2031)

Meticulous Research®, a leading global market research company, published a research report titled, ‘Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) – Forecast to 2031.’

According to this latest publication from Meticulous Research®, the Middle East In Vitro Diagnostics (IVD) market is expected to reach $2.15 billion by 2031 at a CAGR of 4.1% from 2024 to 2031. The growth of the Middle East IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising healthcare expenditures, growth in the aging population, and rising awareness about healthcare. However, high prices for IVD tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market.

The rising awareness regarding early disease diagnosis and increasing inclination toward personalized medicine in the UAE and Saudi Arabia are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.

Key Players

The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy).

Middle East IVD Market: Future Outlook

The Middle East IVD market is segmented by Offering (Kits & Reagents, Instruments, and Software & Services), Technology (Immunoassay/Immunochemistry, Biochemistry/

Middle East IVD Market – Opportunity Analysis and Industry Forecast (2024-2031)

Meticulous Research®, a leading global market research company, published a research report titled, ‘Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) – Forecast to 2031.’

According to this latest publication from Meticulous Research®, the Middle East In Vitro Diagnostics (IVD) market is expected to reach $2.15 billion by 2031 at a CAGR of 4.1% from 2024 to 2031. The growth of the Middle East IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising healthcare expenditures, growth in the aging population, and rising awareness about healthcare. However, high prices for IVD tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market.

The rising awareness regarding early disease diagnosis and increasing inclination toward personalized medicine in the UAE and Saudi Arabia are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.

Key Players

The key players operating in the Middle East IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), QuidelOrtho Corporation. (U.S.), Agilent Technologies, Inc. (U.S.), and DiaSorin S.p.A. (Italy).

Middle East IVD Market: Future Outlook

The Middle East IVD market is segmented by Offering (Kits & Reagents, Instruments, and Software & Services), Technology (Immunoassay/Immunochemistry, Biochemistry/